Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

LL-37 IgG levels are associated with clinical characteristics and T follicular cell response in acute coronary syndrome in adults.

Physiological reports·2026

Same author

Collecting Duct-Targeted Lipid Nanoparticles Deliver <i>Pkd2</i> mRNA to Restore Polycystin-2 and Attenuate ADPKD.

bioRxiv : the preprint server for biology·2026

Same author

Adaptive immune response to the autoantigen LL-37 differentiates atherosclerotic cardiovascular disease phenotypes.

Clinical & translational immunology·2026

Same author

Modulating adaptive immunity by targeting plaque macrophages to reduce atherosclerosis progression.

European heart journal·2026

Same author

Investigation of Urinary Extracellular Vesicles as Novel and Safe Therapeutics for Autosomal Recessive Polycystic Kidney Disease (ARPKD).

Journal of biomedical materials research. Part A·2026

Same author

Myeloid Fmr1 deficiency in mice results in reduced serum cholesterol and altered bile pathway gene expression.

PloS one·2026

Search research articles

Related Experiment Video

Updated: Sep 24, 2025

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

Immunization using ApoB-100 peptide-linked nanoparticles reduces atherosclerosis.

Kuang-Yuh Chyu¹, Xiaoning Zhao¹, Jianchang Zhou¹

¹Oppenheimer Atherosclerosis Research Center, Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.

|May 10, 2022

Summary

Active immunization with apolipoprotein B-100 (ApoB-100) peptide P210, delivered via nanoparticles, reduced atherosclerosis in mice. This P210-nanoparticle vaccine shows promise for treating cardiovascular disease.

Keywords:

Adaptive immunity Atherosclerosis Cardiology T cells Vaccines

More Related Videos

Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis

Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis

Published on: March 22, 2016

Antigenic Liposomes for Generation of Disease-specific Antibodies

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Related Experiment Videos

Last Updated: Sep 24, 2025

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis

Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis

Published on: March 22, 2016

Antigenic Liposomes for Generation of Disease-specific Antibodies

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Area of Science:

Immunology
Cardiovascular Research
Nanotechnology

Background:

Apolipoprotein B-100 (ApoB-100) peptide P210 has shown potential in reducing experimental atherosclerosis.
Nanoparticle delivery systems offer a clinically relevant approach for antigen delivery.

Purpose of the Study:

To explore P210 delivered via self-assembling peptide amphiphile micelles (P210-PAMs) as a vaccine formulation for atherosclerosis.
To assess the efficacy and mechanisms of P210-PAM immunization in mouse models and evaluate its translational potential.

Main Methods:

Characterized T cell responses to P210 in patients with atherosclerotic cardiovascular disease (ASCVD).
Investigated P210-PAMs in ApoE-/- mice and a humanized mouse model.
Analyzed T cell responses, macrophage phenotype, and aortic atherosclerosis reduction.

Main Results:

P210 induced T cell activation and memory responses in ASCVD patients.
P210-PAMs were effectively taken up by dendritic cells.
Immunization with P210-PAMs reduced atherosclerosis in ApoE-/- and humanized mice, modulating T cell and macrophage responses.

Conclusions:

P210-PAMs represent a viable vaccine formulation for targeting atherosclerosis.
This approach demonstrates potential for clinical translation in treating human ASCVD.